{
    "2021-04-05": [
        [
            {
                "time": "",
                "original_text": "医药行业一周观察：调整后重归均衡 关注内生成长明确的一二线公司",
                "features": {
                    "keywords": [
                        "医药行业",
                        "调整",
                        "均衡",
                        "内生成长",
                        "一二线公司"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021年4月投资策略：业绩驱动渐入佳境",
                "features": {
                    "keywords": [
                        "医药行业",
                        "2021年4月",
                        "投资策略",
                        "业绩驱动",
                        "渐入佳境"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}